1. Media & Marketing

Drug Channels News Roundup, June 2025: PBM Rebate Flow, 340B’s 2024 Boom, IRA Fallout, MFN Legal Risks—and Mark Cuban’s PBM Rant

Written by Posted on Less than 0 min read

Happy 249th birthday, America! Before you launch your July 4 festivities, Drug Channels humbly offers some fact-based fireworks to heal our troubled nation:

Plus, Mark Cuban’s blunt take on why CEOs fuel the PBM status quo.

P.S. Join my nearly 64,000 LinkedIn followers for daily links to neat stuff, along with sharp and thoughtful commentary from the Drug Channels community.

Read more »

© 2006-2025 HMP Omnimedia, LLC d/b/a Drug Channels Institute, an HMP Global Company. All rights reserved. This Feed is for personal non-commercial use only.

       
View Original Article
Post Views: 44
Member since
Expert insights from Dr. Adam J. Fein on pharmaceutical economics and the drug distribution system. https://www.drugchannels.net/
Do you like Drug Channels's articles? Follow on social!

More from Drug Channels

  1. Trends & External Forces

Drug Channels News Roundup, November 2024: Employers & Their PBMs, Medicaid vs. 340B, U.S. Drug Prices, and Dr. G Shops for Health Plans

Happy Thanksgiving, everyone! Before you stretch your stomach, stretch your mind with our extra-stuffed helping of food for thought. In this issue: Intriguing data on how employers oversee their PBMs State Medicaid programs carve out PBMs—and get a 340B windfall Are U.S. drug prices really higher than other countries? Plus, Dr. Glaucomflecken gets us ready […]
2 min read
0
  1. Data & Insights

The End of the Blockbuster Era: Unlocking Growth with Direct-to-Patient Commercialization

Today’s guest post comes from Greg Skalicky, President of EVERSANA. Greg discusses some of the challenges manufacturers face with product commercialization, patient access and adherence, and negotiating partnerships with pharmacy benefit managers (PBMs). He introduces us to EVERSANA DIRECT Commercialization™, a direct-to-patient change/model. To learn more about EVERSANA DIRECT Commercialization™ and how the direct-to-patient model […]
2 min read
0
  1. Department: HBC

The Top Pharmacy Benefit Managers of 2024: Market Share and Key Industry Developments

Three’s still company in the world of pharmacy benefit managers. For 2024, nearly 80% of all equivalent prescription claims were processed by three familiar companies: the CVS Caremark business of CVS Health, the Express Scripts business of Cigna, and the Optum Rx business of UnitedHealth Group. The names haven’t changed, but shifting relationships and contract […]
2 min read
0
  1. Trends & External Forces

NEW: The Drug Channels 2025 Video Webinar Series

Drug Channel Institute is pleased to announce The Drug Channels 2025 Video Webinar Series. Join Dr. Adam J. Fein for three live video webinars during 2025. These live, interactive events will be broadcast via Zoom from the Drug Channels Video studio in beautiful downtown Philadelphia. During these events, Dr. Fein will address the latest issues […]
3 min read
0
  1. Department: HBC

Available for Preorder: The 2025 Economic Report on U.S. Pharmacies and Pharmacy Benefit Managers

On March 18, 2025, Drug Channels Institute will release The 2025 Economic Report on U.S. Pharmacies and Pharmacy Benefit Managers. This report—our sixteenth edition—remains the most comprehensive, fact-based tool for understanding the entire U.S. drug pricing, reimbursement, and dispensing system. This unique, encyclopedic resource is your ultimate guide to the complex web of interactions within […]
3 min read
0
  1. Trends & External Forces

U.S. Brand-Name Drug Prices Fell in 2025 as the Net Pricing Drug Channel Emerges

It’s time for Drug Channels’ annual examination of U.S. brand-name drug pricing. For 2025, brand-name drugs’ average list prices grew by only 3.5%, but net prices declined. When manufacturers’ rebates and discounts are factored in, drugs’ average net prices—both before and after inflation—fell. Details and additional commentary below. As I have been predicting, the gross-to-net […]
2 min read
0
  1. Merchandising

Available for Preorder: The 2024-25 Economic Report on Pharmaceutical Wholesalers and Specialty Distributors

On October 8, 2024, Drug Channels Institute will release our 2024-25 Economic Report on Pharmaceutical Wholesalers and Specialty Distributors. This report—our fifteenth edition—remains the most comprehensive, fact-based tool for understanding and analyzing the large and growing U.S. pharmaceutical distribution industry. 9 chapters, 350+ pages, 178 exhibits, 750+ endnotes: There is nothing else available that comes close […]
2 min read
0
  1. Data & Insights

Vertical Integration Redux: How Pharmaceutical Wholesalers Are Transforming the Buy-and-Bill Market (rerun)

This week, I’m rerunning some popular posts while I prepare for tomorrow’s live video webinar: PBM Industry Update: Trends, Challenges, and What’s Ahead. Click here to see the original post from February 2025. ICYMI, the largest three pharmaceutical wholesalers—Cardinal Health, Cencora, and McKesson—are using vertical integration to build significant market positions in businesses beyond drug […]
3 min read
0
  1. Trends & External Forces

Inflation-Adjusted U.S. Brand-Name Drug Prices Fell for the Seventh Consecutive Year as a New Era of Drug Pricing Dawns (rerun)

This week, I’m rerunning some popular posts while I prepare for today’s live video webinar: PBM Industry Update: Trends, Challenges, and What’s Ahead. Click here to see the original post from January 2025. It’s time for Drug Channels’ annual examination of U.S. brand-name drug pricing. For 2024, average brand-name drugs’ list prices grew by only […]
3 min read
0
  1. Data & Insights

The $700 Copay That Changed Everything

Today’s guest post comes from Stephen Hom, EVP, Chief Commercial Officer, and Co-Founder of RIS Rx. Stephen argues that patient affordability remains one of the most critical—and often overlooked—barriers to treatment adherence. Drawing on his experience as a community pharmacist, he suggests that cost isn’t just a financial issue—it’s a clinical one. To learn about […]
2 min read
0
  1. Media & Marketing

Follow the 340B Prescription Dollar: How PBMs Profit from 340B Contract Pharmacies (rerun)

This week, I’m rerunning some popular posts while I prepare for Friday’s Drug Channels Outlook 2025 live video webinar. During the webinar, I’ll provide an update the 340B program, which continues to defy gravity. Click here to see the original post. In my recent The 340B Drug Pricing Program: Trends, Controversies, and Outlook video webinar, I […]
2 min read
0
  1. Data & Insights

Four Revelations from Minnesota’s First 340B Transparency Report (rerun)

This week, I’m rerunning some popular posts while I prepare for Friday’s live video webinar: PBM Industry Update: Trends, Challenges, and What’s Ahead. Click here to see the original post from December 2024. It’s time to pay attention to the money behind the 340B curtain. Minnesota just released the industry‘s first ever mandated financial report […]
2 min read
0
  1. Media & Marketing

340B Hit $81 Billion in 2024: Why CMS and the IRA Are Poised to Cool the Program’s Runaway Growth (VIDEO)

Yesterday, I published 340B Hit $81 Billion in 2024 (+23%): Why CMS and the IRA Are Poised to Cool the Program’s Runaway Growth. For those who prefer watching to reading, I asked AI to turn our latest 340B analysis into a tidy little video. Let me know what you think of this format and whether […]
2 min read
0
  1. Channel: Drug

Can Rite Aid Recover?

Last fall, poor ol’ Rite Aid finally succumbed to bankruptcy. It was pretty much the definition of an expected surprise. To get a comprehensive look at the company’s ever-declining fortunes, DCI rummaged around the compnay’s numerous bankruptcy filings. Below, you’ll find our review of Rite Aid’s current financial situation, shrinking store footprint, changing relationship with […]
2 min read
0
  1. Trends & External Forces

Medicare Part D in 2025: Preferred Pharmacy Networks Fade in a Collapsing PDP Market

Uh oh. As I predicted, the stand-alone Medicare Part D prescription drug plans (PDP) market is vanishing. For 2025, DCI’s exclusive analysis of Center for Medicare & Medicaid Services’ (CMS) data reveals that the number of PDPs will drop to a historic low. What’s more, the share of plans with a preferred cost sharing pharmacy […]
3 min read
0
  1. Media & Marketing

Reimagining Patient Access: Building Direct-to-Consumer Models for a New Regulatory Era

Today’s guest post comes from Jordan Armstrong, VP of Business Development at AssistRx. Jordan examines the growing role of direct-to-consumer (DTC) access models in the pharmaceutical sector. He discusses recent regulatory developments, the potential benefits and risks for manufacturers, and key considerations for building sustainable DTC programs. To learn more, register for AssistRx’s October 21st […]
2 min read
0
  1. Media & Marketing

Drug Channels News Roundup, December 2025: The Net Pricing Drug Channel (#NPDC) Era, LillyDirect, My $0.02 on New MFPs, PBMs in Medicaid—and DCLF 2026

Happy New Year, everyone! As always, thank you for welcoming Drug Channels into your inboxes, browsers, and apps. I’m continually inspired by the diverse and thoughtful people who follow, share, and challenge our work. Our DCI community now includes more than 110,000 subscribers and followers across the industry. If you haven’t already done so, you […]
2 min read
0
  1. Trends & External Forces

Why 340B Reform Could Happen in 2025 (video)

During my recent Drug Channels Outlook 2025 video webinar, I tackled a wide range of crucial topics—including the controversial 340B Drug Pricing Program. As I explain in this video excerpt, we may finally see reform of this rapidly expanding program. What’s more, implementing the Inflation Reduction Act will disrupt the current operations of the 340B […]
2 min read
0
  1. Trends & External Forces

Drug Channels News Roundup, May 2025: MFN Controversy, Plan Sponsors ♥️ Rebates, PBM Profits, and Fun in Congress

Summer unofficially began over the weekend. To mark the occasion, here are a few hot items, freshly seared on the Drug Channels grill: Reactions from the Drug Channels community to the Most Favored Nation (MFN) pricing policy A reality check on whether plan sponsors truly want rebate reform What plan sponsors should know about the […]
2 min read
0
  1. Trends & External Forces

NEW: The Drug Channels 2026 Video Webinar Series

Join Dr. Adam J. Fein, president of Drug Channels Institute (DCI), for three new video webinars during 2026. These live, interactive events are designed for executives who need timely insight into the rapidly changing U.S. drug channel. They will be broadcast via Zoom from the Drug Channels Video studio in beautiful downtown Philadelphia. Register Now […]
4 min read
0
Next